Sharing a long and relevant post from CTMedic on t
Post# of 36537
(Total Views: 364)
Posted On: 08/21/2020 12:09:05 PM
Sharing a long and relevant post from CTMedic on the CYDY board. RJS should enjoy reading while healing:
"CytoDyn Inc CYDY
Posted On: 08/21/2020 12:28:06 AM
Post# 51050 of 51069

Replies (4)
Posted By: CTMedic
A super long winded, but I hope reasonably clear email I sent to my brother, to help his non-medical colleagues understand why we have lost our minds and raided the children's piggy banks to buy more shares of a pink sheet stock.
I hope you are well. I am pleased that you are sharing with your colleagues information about Leronlimab, a therapeutic monoclonal antibody which is on the cusp of approval, with blockbuster, if not paradigm shifting potential.
I am not often brief, but will try to be clear. I believe you are reaching out to medical and non-medical colleagues, so I will try not to embarrass myself to the physicians with whom you may share.
When a virus invades the body, it infects and kills cells, as it hijacks the cellular apparatus to replicate itself. Injured and infected cells respond to this attack by releasing cytokines, which are chemical messengers which "call for help", initiating an inflammatory response to fight the infection. A subset of cytokines are chemokines (chemotaxic cytokines), which mobilize infection fighting cells to areas of tissue damage and inflammation.
One of the principal chemokines in the activation of the immune system is CCL5 or RANTES. RANTES is released by a number of cell types, but in Covid infection, it is importantly released by injured epithelial cells in the lungs. White blood cells, including T cells and macrophages respond to the site of infection. Unfortunately in severe Covid disease, the injured cells continue to release RANTES. More inflammatory cells migrate to areas of inflammation, creating a viscous circle, eventually escalating to the "cytokine storm". The excess migration of these cells to the lungs is a large component of the acute respiratory distress syndrome and pulmonary collapse in severe covid. A cascade of other cytokines are released as part of an inflammatory cascade, including interleukin 6 and TNF-alpha, which have been the target of other unsuccesful Covid treatments. The combination of extreme cytokine levels and excess activation and mobilization of inflammatory cells results in a profound immune dysregulation. This is profoundly injurious and eventually deadly.
In some ways, it is akin to having 100,000 uncontrolled mercenaries respond to a conflict, rather than 100 disciplined and effective Navy Seals.
Excess stimulation of the cytokine storm eventually exhausts the ability of these immune fighting cells to function properly. Macrophages, a type of white blood cell, become polarized and act in an inflammatory fashion, rather than helpfully devouring viruses and infected cells. T cells, rather than producing granzyme-a, an important enzyme to kill infected cells, lie about helplessly.
Now to the good part.
Leronlimab is a monoclonal antibody, which was designed to treat HIV. It blocks the binding site (the doorway) on the CCR5 receptor, the primary site to which CCL5/RANTES binds. Leronlimab is awaiting approval for HIV. The HIV virus enters T cells through CCR5, infecting and killing them and destroying a major part of the immune system. Leronlimab "blocks this door", preventing HIV entry, and returning patients to health. Trial patients have had undetectable levels of HIV virus for six while taking leronlimab, all without taking any antiviral medication. The immune system, when not damaged, clears the virus by itself.
In covid, administration of leronlimab blocks the same CCR5 receptor. By blocking CCR5, immune cells no longer migrate to areas of inflammation, preventing runaway inflammation and reversing the disproportionate inflammation of the cytokine storm.
Additionally, by blocking CCR5 on macrophages, the macrophages are repolarized/restored to normal viral fighting function.
T cells, which become useless in response to excess RANTES, reverse their cellular exhaustion and function normally. They excrete granzyme-A once more, lysing (killing) virally infected cells and stopping production of more Covid viruses.
So, one medication, Leronlimab:
1. Stops the cytokine storm
2. Reverses cellular exhaustion/repolarizes macrophages and allows return to normal immune function.
3. Reverse viremia (clears covid virus from the bloodstream).
Now the great part, blockbuster potentional:
Leronlimab has no significant side effects, in more than 1,000 patients over six years.
It successfully treats Covid and HIV.
The same inflammatory pathway of immune dysregulation after infection is responsible for the majority of pathogenicity in a host of illnesses.
Leronlimab is likely to be the effective treatment for severe seasonal and pandemic influenza.
It should be the cure for sepsis.
RANTES and immune dysregulation results in chronic inflammation and dozens of diseases affecting millions of patients.
These include multiple sclerosis, Alzheimer's, Parkinson's, lupus, crohn's disease, amyolateral sclerosis, Guillan-Barre and symptoms of post-Lyme infection.
As an aside, leronlimab also apparently blocks tumor metastases in a number of solid tumor cancers, including breast, prostate, colon and bladder.
In an initial trial of 12 women with Tnbc (triple negative breast cancer, meaning cancer tumor cells without any of the three common cell proteins targeted by chemotherapy, with a resultant grave prognosis), circulating tumor cells went to ZERO. This means that metastasis was stopped in its tracks. Metastasis is what causes death in 90% of solid tumor cancers.
Cytodyn filed for Emergency Use Authorization for leronlimab in covid-19 disease August 12 and has now been invited to participate in Operation Warp Speed to accelerate its ability to produce leronlimab in larger quantities.
Cytodyn also applied to UK MHRA for Fast Track approval in covid 19 on August 18, with a decision due within 24 hours.
The mechanism of action (MOA) for leronlimab in Covid is eloquently demonstrated by Dr. Bruce Patterson in this manuscript:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/
He discussed his findings here: https://www.youtube.com/watch?v=3PsSH0Hlas4
The MOA for leronlimab in cancer is explained well in this video on Cytodyn's website:https://www.dropbox.com/s/2uu5xp6fffzpwew/CytoDyn%20Leronlimab.mp4?dl=0
I hope this helps. Too much to be brief, but this is an opportunity nearly beyond comprehension.
Annual sales for cancer and HIV alone, could produce a market capitalization in excess of $100B ($120/share). Fully realizing the potential in ALzheimers, Parkinsons and all the autoimmune disorders could have the company in ten years' time at $500 billion.
This is what keeps me up all night.
Not an opportunity to be dismissed out of hand."
"CytoDyn Inc CYDY
Posted On: 08/21/2020 12:28:06 AM
Post# 51050 of 51069

Replies (4)
Posted By: CTMedic
A super long winded, but I hope reasonably clear email I sent to my brother, to help his non-medical colleagues understand why we have lost our minds and raided the children's piggy banks to buy more shares of a pink sheet stock.
I hope you are well. I am pleased that you are sharing with your colleagues information about Leronlimab, a therapeutic monoclonal antibody which is on the cusp of approval, with blockbuster, if not paradigm shifting potential.
I am not often brief, but will try to be clear. I believe you are reaching out to medical and non-medical colleagues, so I will try not to embarrass myself to the physicians with whom you may share.
When a virus invades the body, it infects and kills cells, as it hijacks the cellular apparatus to replicate itself. Injured and infected cells respond to this attack by releasing cytokines, which are chemical messengers which "call for help", initiating an inflammatory response to fight the infection. A subset of cytokines are chemokines (chemotaxic cytokines), which mobilize infection fighting cells to areas of tissue damage and inflammation.
One of the principal chemokines in the activation of the immune system is CCL5 or RANTES. RANTES is released by a number of cell types, but in Covid infection, it is importantly released by injured epithelial cells in the lungs. White blood cells, including T cells and macrophages respond to the site of infection. Unfortunately in severe Covid disease, the injured cells continue to release RANTES. More inflammatory cells migrate to areas of inflammation, creating a viscous circle, eventually escalating to the "cytokine storm". The excess migration of these cells to the lungs is a large component of the acute respiratory distress syndrome and pulmonary collapse in severe covid. A cascade of other cytokines are released as part of an inflammatory cascade, including interleukin 6 and TNF-alpha, which have been the target of other unsuccesful Covid treatments. The combination of extreme cytokine levels and excess activation and mobilization of inflammatory cells results in a profound immune dysregulation. This is profoundly injurious and eventually deadly.
In some ways, it is akin to having 100,000 uncontrolled mercenaries respond to a conflict, rather than 100 disciplined and effective Navy Seals.
Excess stimulation of the cytokine storm eventually exhausts the ability of these immune fighting cells to function properly. Macrophages, a type of white blood cell, become polarized and act in an inflammatory fashion, rather than helpfully devouring viruses and infected cells. T cells, rather than producing granzyme-a, an important enzyme to kill infected cells, lie about helplessly.
Now to the good part.
Leronlimab is a monoclonal antibody, which was designed to treat HIV. It blocks the binding site (the doorway) on the CCR5 receptor, the primary site to which CCL5/RANTES binds. Leronlimab is awaiting approval for HIV. The HIV virus enters T cells through CCR5, infecting and killing them and destroying a major part of the immune system. Leronlimab "blocks this door", preventing HIV entry, and returning patients to health. Trial patients have had undetectable levels of HIV virus for six while taking leronlimab, all without taking any antiviral medication. The immune system, when not damaged, clears the virus by itself.
In covid, administration of leronlimab blocks the same CCR5 receptor. By blocking CCR5, immune cells no longer migrate to areas of inflammation, preventing runaway inflammation and reversing the disproportionate inflammation of the cytokine storm.
Additionally, by blocking CCR5 on macrophages, the macrophages are repolarized/restored to normal viral fighting function.
T cells, which become useless in response to excess RANTES, reverse their cellular exhaustion and function normally. They excrete granzyme-A once more, lysing (killing) virally infected cells and stopping production of more Covid viruses.
So, one medication, Leronlimab:
1. Stops the cytokine storm
2. Reverses cellular exhaustion/repolarizes macrophages and allows return to normal immune function.
3. Reverse viremia (clears covid virus from the bloodstream).
Now the great part, blockbuster potentional:
Leronlimab has no significant side effects, in more than 1,000 patients over six years.
It successfully treats Covid and HIV.
The same inflammatory pathway of immune dysregulation after infection is responsible for the majority of pathogenicity in a host of illnesses.
Leronlimab is likely to be the effective treatment for severe seasonal and pandemic influenza.
It should be the cure for sepsis.
RANTES and immune dysregulation results in chronic inflammation and dozens of diseases affecting millions of patients.
These include multiple sclerosis, Alzheimer's, Parkinson's, lupus, crohn's disease, amyolateral sclerosis, Guillan-Barre and symptoms of post-Lyme infection.
As an aside, leronlimab also apparently blocks tumor metastases in a number of solid tumor cancers, including breast, prostate, colon and bladder.
In an initial trial of 12 women with Tnbc (triple negative breast cancer, meaning cancer tumor cells without any of the three common cell proteins targeted by chemotherapy, with a resultant grave prognosis), circulating tumor cells went to ZERO. This means that metastasis was stopped in its tracks. Metastasis is what causes death in 90% of solid tumor cancers.
Cytodyn filed for Emergency Use Authorization for leronlimab in covid-19 disease August 12 and has now been invited to participate in Operation Warp Speed to accelerate its ability to produce leronlimab in larger quantities.
Cytodyn also applied to UK MHRA for Fast Track approval in covid 19 on August 18, with a decision due within 24 hours.
The mechanism of action (MOA) for leronlimab in Covid is eloquently demonstrated by Dr. Bruce Patterson in this manuscript:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/
He discussed his findings here: https://www.youtube.com/watch?v=3PsSH0Hlas4
The MOA for leronlimab in cancer is explained well in this video on Cytodyn's website:https://www.dropbox.com/s/2uu5xp6fffzpwew/CytoDyn%20Leronlimab.mp4?dl=0
I hope this helps. Too much to be brief, but this is an opportunity nearly beyond comprehension.
Annual sales for cancer and HIV alone, could produce a market capitalization in excess of $100B ($120/share). Fully realizing the potential in ALzheimers, Parkinsons and all the autoimmune disorders could have the company in ten years' time at $500 billion.
This is what keeps me up all night.
Not an opportunity to be dismissed out of hand."
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼